Summary
Two groups of 20 patients with no evidence of cardiovascular, hepatic, renal or gastrointestinal failure were treated orally for five days with placebo or SB 7505 100 mg/day. No change was observed in heart rate or blood pressure. Urine output, the excretion of Na, K and Cl, and creatinine clearance were significantly increased.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Melloni GF, Minoja GM, Lureti GF, Bagliani M, Pamparana F, Ghirardi P (1979) Clinical pilot trial on SB 7505. Curr Ther Res Clin Exp 26: 466
Kempi V, Persson RBR (1975)99mTc.DTPA (Sn) dry-kit preparation. Quality control and clearance studies. Nucl Med 13: 388
Ferrini R, Miragoli G (1981) Effetto dell'SB 7505 sulla diuresi del ratto sveglio normalmente idratato. (In press)
Merlo L, Brusoni B, Ghirardi P (1979) Effetti dell'estere diisobutirrico della N-metil-dopamina (SB 7505) sulla emodinamica del distretto renale e sulla contrattilità del miocardio del cane anestetizzato. Comunicazione al 40° Congresso della Società Italiana di Cardiologia 24–29 Giugno 1979 (comunicazione nr. 303, p 268)
Dei Cas L, Manca C, Vasini G, Mansour M, Bernardini B, Visioli O (1980) Non-invasive evaluation of left ventricular function through systolic time intervals following oral administration of SB 7505 in man. Arzneim Forsch 30: 498
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Melloni, G.F., Minoja, G.M., Scorazzati, G. et al. Renal effects of SB 7505: A double-blind study. Eur J Clin Pharmacol 19, 177–180 (1981). https://doi.org/10.1007/BF00561945
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00561945